
    
      PROTOCOL OUTLINE: This is an open label, multicenter study. Patients should begin therapy
      within 72 hours of hospital admission, but may receive human botulism immunoglobulin (BIG) in
      certain circumstances after 72 hours. Patients receive (BIG) IV. Patients are monitored for
      side effects, disease severity, complications, and length of hospital stay.

      Patients are followed at 2 weeks after treatment, then every 4 weeks for 6 months.

      Completion date provided represents the completion date of the grant per OOPD records
    
  